Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of April 2022. The report serves as a notification to the market regarding the Company's total voting rights and capital structure as of March 31, 2022, in conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure details:
- Issued Share Capital: 5,388,804,119 Ordinary Shares of 25 pence each as of March 31, 2022.
- Treasury Shares: 304,905,950 Ordinary Shares held in Treasury.
- Total Voting Rights: 5,083,898,169.
Material Changes
The filing text does not provide comparative data against prior periods to identify material changes in share capital or voting rights.
Guidance, Outlook, and Risks
The document contains no management commentary, financial guidance, outlook, risk factors, contingencies, or unusual items. Its sole purpose is to establish the denominator for shareholder notification calculations under FCA rules.
Investor Verification Checklist
- Verify the total number of voting rights (5,083,898,169) for compliance with FCA disclosure thresholds.
- Confirm the count of Treasury Shares (304,905,950) held as of March 31, 2022.
- Note that this filing does not contain operational or financial performance results; refer to Form 20-F or quarterly earnings releases for such data.